Chemoembolization and radioembolization

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 5, 2014, Pages 909-919

  Sangro, Bruno ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

DEB; Drug eluting beads; Radioembolization; RE; Selective internal radiation therapy; SIRT; TACE; Transarterial chemoembolization; Yttrium

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTIFICIAL EMBOLISM; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG DELIVERY DEVICE; DRUG ELUTING BEAD; EMBOLIC PARTICLE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; RADIOEMBOLIZATION; REVIEW; TUMOR ABLATION; TUMOR NECROSIS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84921460302     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.08.009     Document Type: Review

References (90)

1. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. YGAST 2005 Aug; 129 (2) : 486-93.
2. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatol Baltim Md 2011: 1020-2.
3. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012 Apr; 56 (4) : 908-43.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012 Mar 31; 379 (9822) : 1245-55.
5. D'Avola D, Iñarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 2011 Jul; 18 (7) : 1964-71.
6. Bilbao JI, de Luis E, García de Jalón JA, de Martino A, Lozano MD, la Cuesta de AM, et al. Comparative study of four different spherical embolic particles in an animal model: A morphologic and histologic evaluation. J Vasc Interv Radiol 2008 Nov; 19 (11) : 1625-38.
7. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011 May; 37 (3) : 212-20.
8. Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, et al. Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996 Jan; 198 (1) : 33-40.
9. Pietrosi G, Miraglia R, Luca A, Vizzini GB, Fili D, Riccardo V, et al. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: A safe standardized protocol in selected patients with child class A and B cirrhosis. J Vasc Interv Radiol 2009 Jul; 20 (7) : 896-902.
10. Yu J-S, Kim KW, Jeong M-G, Lee DH, Park M-S, Yoon S-W. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Interv Radiol 2002 Jul; 25 (4) : 270-4.
11. Luo J, Guo R-P, Lai ECH, Zhang Y-J, Lau W-Y, Chen M-S, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: A prospective comparative study. Ann Surg Oncol 2011 Feb; 18 (2) : 413-20.
12. Xia J, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006 Sep; 59 (3) : 407-12.
13. Belli L, Magistretti G, Puricelli GP, Damiani G, Colombo E, Cornalba GP. Arteritis following intra-arterial chemotherapy for liver tumors. Eur Radiol 1997; 7 (3) : 323-6.
14. Cammá C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002 Jul 1; 224 (1) : 47-54.
15. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006 Aug; 131 (2) : 461-9.
16. Llovet JM, Real MI, Montañá X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002 May 18; 359 (9319) : 1734-9.
17. Lo C. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 May; 35 (5) : 1164-71.
18. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 2007 Jan; 30 (1) : 6-25.
19. Llovet J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003 Feb; 37 (2) : 429-42.
20. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, et al. Chemoembolization for hepatocellular carcinoma: Comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010 May 25; 255 (3) : 955-65.
21. O'Suilleabhain CB, Poon RTP, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003 Mar; 90 (3) : 325-31.
22. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST,Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000 Feb; 73 (2) : 109-14.
23. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: A retrospective analysis. AJR - Am J Roentgenol 2000 Dec; 175 (6) : 1665-72.
24. Herber SCA, Otto G, Schneider J, Schuchmann M, Düber C, Pitton MB, et al. Transarterial chemoembolization in patients not eligible for liver transplantation: Single-center results. Am J Roentgenol 2008 Apr; 190 (4) : 1035-42.
25. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012 Apr; 56 (4) : 886-92.
26. Kim KM, Kim JH, Park IS, Ko G-Y, Yoon H-K, Sung K-B, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009 May; 24 (5) : 806-14.
27. Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 Sep; 35 (3) : 421-30.
28. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 Feb; 30 (1) : 52-60.
29. Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 2013 Jun; 58 (6) : 1181-7.
30. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) . Ann Oncol 2013 Apr; 24 (4) : 965-73.
31. Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han K-H, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013 Mar; 49 (4) : 826-34.
32. Park J-W, Amarapurkar D, Chao Y, Chen P-J, Geschwind J-FH, Goh KL, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) . 2013 327-37.
33. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, et al. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013 Jun; 57 (6) : 2261-73.
34. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) . J Surg Oncol 2010 May 1; 101 (6) : 476-80.
35. Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead™: Results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Interv Radiol 2011 Aug; 34 (4) : 774-85.
36. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial. Am J Roentgenol 2011 Oct; 197 (4) : W562-70.
37. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicineluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis. Cardiovasc Interv Radiol 2012 Oct; 35 (5) : 1119-28.
38. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007 Mar; 46 (3) : 474-81.
39. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A,Watkinson A, et al. Prospective randomized study of doxorubicin-elutingbead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Interv Radiol 2010 Feb; 33 (1) : 41-52.
40. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Interv Radiol 2010 Jun; 33 (3) : 541-51.
41. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012 Jun; 56 (6) : 1330-5.
42. Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: An international working group report. Am J Clin Oncol 2011 Jun; 34 (3) : 337-41.
43. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (TheraSphere®) : Assessment of hepatic arterial embolization. Cardiovasc Interv Radiol 2006 Apr 29; 29 (4) : 522-9.
44. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011 Jun 30; 54 (3) : 868-78.
45. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995 Nov 1; 33 (4) : 919-24.
46. Carr BI. Hepatic arteria l90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients. Liver Transpl 2004; 10 (S2) : S107-10.
47. Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 2007 Jun; 102 (6) : 1216-20.
48. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010 Oct 29; 52 (5) : 1741-9.
49. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008 Jan 2; 47 (1) : 71-81.
50. Geschwind J-FH, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004 Nov; 127 (5) : S194-205.
51. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere) : Safety, tumor response, and survival. J Vasc Interv Radiol 2005 Dec; 16 (12) : 1627-39.
52. Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? ACS - Am Coll Surg 2009 Mar 1; 208 (3) : 375-82.
53. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013 Mar; 57 (3) : 1078-87.
54. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol Eur Assoc Study Liver 2012 Feb 1; 56 (2) : 464-73.
55. Lau W-Y, Kennedy AS, Kim YH, Lai HK, Lee R-C, Leung TWT, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012 Jan 1; 82 (1) : 401-7.
56. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006 Nov; 66 (3) : 792-800.
57. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 2010 Jan 1; 138 (1) : 52-64. Elsevier Inc.
58. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011 Aug; 141 (2) : 526-35. 535.e1-2.
59. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediateadvanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013 May; 57 (5) : 1826-37.
60. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011 Feb; 140 (2) : 497-507. e2.
61. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013 Oct; 11 (10) : 1358-65. e1.
62. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology 2013 Dec; 58 (6) : 2188-97.
63. Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011 Jan 1; 79 (1) : 163-71. Elsevier Ltd.
64. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2008 Nov 19; 49 (4) : 1185-93.
65. Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Interv Radiol 2010 Dec; 33 (6) : 1143-52.
66. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (
67. Fernandez-Ros N, Iñarrairaegui M, Paramo JA, Berasain C, Avila MA, Chopitea A, et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int 2014 May 16.
68. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: Preliminary findings of hepatic volumetric response to lobar Yttrium-90 radioembolization. Ann Surg Oncol 2009 Apr 9; 16 (6) : 1587-96.
69. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (Thera-Sphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94 (7) : 572-86.
70. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization. Am J Transplant 2009 Aug; 9 (8) : 1920-8.
71. Iñarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D'Avola D, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012 Mar 20: 1-8. Elsevier Ltd.
72. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24; 359 (4) : 378-90.
73. Bilbao JI, Martino A, Luis E, Díaz-Dorronsoro L, Alonso-Burgos A, Martínez de la Cuesta A, et al. Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: Histological findings. Cardiovasc Interv Radiol 2009 May 16; 32 (4) : 727-36.
74. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson Al B, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J Hepatol Eur Assoc Study Liver 2012 Sep 18: 1-29.
75. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 Jan 1; 10 (1) : 25-34. Elsevier Ltd.
76. Iñarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodríguez M, Arbizu J, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010 Aug; 21 (8) : 1205-12.
77. Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxì A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 2012 Oct; 57 (4) : 821-9.
78. Bolondi L, Burroughs A, Dufour J-F, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular Carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012 Nov; 32 (4) : 348-59.
79. Shim JH, Park J-W, Kim JH, An M, Kong S-Y, Nam B-H, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008 Oct; 99 (10) : 2037-44.
80. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) : The role of angiogenesis and invasiveness. Am J Gastroenterol 2008 Apr; 103 (4) : 914-21.
81. Strebel BM, Dufour J-F. Combined approach to hepatocellular carcinoma: A new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008 Nov; 8 (11) : 1743-9.
82. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011 Sep; 47 (14) : 2117-27.
83. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JFH. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011 Oct 18; 29 (30) : 3960-7.
84. Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, Moore DF, et al. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Interv Radiol 2014 Feb; 25 (2) : 297-306. e1.
85. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatinbased sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013 Apr 2; 108 (6) : 1252-9.
86. Wang J-H, Changchien C-S, Hu T-H, Lee C-M, Kee K-M, Lin C-Y, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - survival analysis of 3892 patients. Eur J Cancer 2008 May; 44 (7) : 1000-6.
87. Hsu K-F, Chu C-H, Chan D-C, Yu J-C, Shih M-L, Hsieh H-F, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol 2012 Mar; 81 (3) : 466-71.
88. Ho M-C, Huang G-T, Tsang Y-M, Lee P-H, Chen D-S, Sheu J-C, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009 Apr; 16 (4) : 848-55.
89. Moreno Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol 2013 Jun; 36 (3) : 714-23.
90. Chung GE, Lee J-H, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011 Feb; 258 (2) : 627-34.